Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.51 |
| ▸ | TACR1 | P25103 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | PSMB1 | P20618 | 1/20 | 0.47 |
| ▸ | ACE | P12821 | 1/20 | 0.46 |
| ▸ | CASP1 | P29466 | 5/20 | 0.46 |
| ▸ | MBTPS1 | Q14703 | 1/20 | 0.46 |
| ▸ | MME | P08473 | 1/20 | 0.43 |
| ▸ | ECE1 | P42892 | 1/20 | 0.43 |
| ▸ | PSMB8 | P28062 | 1/20 | 0.43 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11940464 | 0.90 | CASP1 (0.52) | POLBTACR1RAB9AALDH1A1GAA | |
| SCHEMBL30910805 | 0.90 | ACE (0.50) | POLBTACR1RAB9AALDH1A1PSMB1 | |
| SCHEMBL25491959 | 0.88 | MMP9 (0.51) | POLBTACR1RAB9AALDH1A1GAA | |
| SCHEMBL25492010 | 0.86 | ABCB1 (0.47) | POLBTACR1RAB9AALDH1A1GAA | |
| SCHEMBL28252941 | 0.86 | EPHX2 (0.50) | KMT2AACEPSMB5 | |
| SCHEMBL28252940 | 0.86 | EPHX2 (0.50) | KMT2AACEPSMB5 | |
| SCHEMBL21254007 | 0.85 | CASP1 (0.54) | POLBRAB9AALDH1A1ACECASP1 | |
| SCHEMBL25408743 | 0.85 | EPHX2 (0.52) | ALDH1A1KMT2A | |
| SCHEMBL30910821 | 0.85 | EPHX2 (0.52) | ALDH1A1KMT2A | |
| SCHEMBL30910825 | 0.85 | EPHX2 (0.52) | ALDH1A1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9243028-B2 | Facile amide formation via S-nitroso thioacid intermediates | WASHINGTON STATE UNIVERSITY (US) | 2016-01-26 | — | — | US | disclosed |
| US-20120190820-A1 | FACILE AMIDE FORMATION VIA S-NITROSO THIOACID INTERMEDIATES | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2012-07-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120190820-A1 | FACILE AMIDE FORMATION VIA S-NITROSO THIOACID INTERMEDIATES | NAAA, TST, ASNS | POLB 3466/4885TACR1 1386/4885RAB9A 2323/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.